General Internal Medicine

ANCA Vasculitis

Questions discussed in this category

How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?

This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeeting. This question was inspi...

1 Answer available

What is your approach for steroid dosing for patients with ANCA vasculitis on induction treatment with rituximab, avacopan, and glucocorticoid therapy?

1 Answer available

Would you stop azathioprine in a patient with ANCA vasculitis who has been in long term remission on azathioprine, but has a new diagnosis of lung cancer requiring initiation of immunotherapy?

2 Answers available

Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?

2 Answers available

How would you treat a young patient who presents with coronary vasculitis and aortitis with persistently positive MPO but no other features of AAV?

2 Answers available

Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?

This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).

2 Answers available

Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

ADVOCATE trial

1 Answer available

What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide?

1 Answer available

How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?

1 Answer available

Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?

2 Answers available

Papers discussed in this category

Ann. Rheum. Dis., 2018 May 03

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

Ann. Rheum. Dis., 2018 Apr 25

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

N Engl J Med, 2021 Feb 18

Avacopan for the Treatment of ANCA-Associated Vasculitis.

Annals of the rheumatic diseases, 2024 Jan 11

Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015-05

Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

J Immunother Cancer, 2021 Jul

Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016 Jul 07

Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis.

Arthritis & rheumatology (Hoboken, N.J.), 2019 Oct 21

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.

European journal of cancer (Oxford, England : 1990), 2023 Dec 28

Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.

Arthritis and rheumatism, 2006 Mar

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

N Engl J Med, 2020 Feb 13

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

Related Topics in General Internal Medicine